VORICONAZOLE

VORICONAZOLE was reported 30719 times

VORICONAZOLE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 FLUORIDE INCREASED 43 0.8113
1 PERIOSTITIS 236 0.5463
2 FLUOROSIS 44 0.5116
3 CEREBRAL ASPERGILLOSIS 200 0.3252
4 HYPERTROPHIC OSTEOARTHROPATHY 21 0.3088
5 GEOTRICHUM INFECTION 61 0.2891
6 MYCOTIC ENDOPHTHALMITIS 47 0.2487
7 SCEDOSPORIUM INFECTION 174 0.2465
8 FUSARIUM INFECTION 160 0.2286
9 CHLOROPSIA 26 0.2031
10 CENTRAL NERVOUS SYSTEM FUNGAL INFECTION 47 0.2026
11 PHOTODERMATOSIS 84 0.1991
12 CHOROIDITIS 72 0.1925
13 FUNGAL ENDOCARDITIS 56 0.1860
14 DISSEMINATED ASPERGILLOSIS 87 0.1843
15 DISSEMINATED MUCORMYCOSIS 69 0.1751
16 ASPERGILLOMA 56 0.1750
17 OSTEOMYELITIS FUNGAL 29 0.1737
18 ASPERGILLUS TEST POSITIVE 52 0.1688
19 KERATITIS FUNGAL 35 0.1683
20 PULMONARY MUCORMYCOSIS 86 0.1629
21 ZYGOMYCOSIS 73 0.1560
22 SYSTEMIC MYCOSIS 176 0.1507
23 DILATATION INTRAHEPATIC DUCT ACQUIRED 42 0.1438
24 ASPERGILLUS INFECTION 943 0.1435
25 TOXIC OPTIC NEUROPATHY 61 0.1406
26 MUCORMYCOSIS 360 0.1384
27 ABSCESS FUNGAL 24 0.1371
28 BRONCHOPULMONARY ASPERGILLOSIS 1063 0.1370
29 LIP SQUAMOUS CELL CARCINOMA 21 0.1250
30 XANTHOPSIA 46 0.1247
31 CEREBRAL FUNGAL INFECTION 33 0.1166
32 TRICHOSPORON INFECTION 47 0.1160
33 ACTINIC KERATOSIS 297 0.1143
34 ASPERGILLOSIS 143 0.1094
35 EYE INFECTION FUNGAL 39 0.1008
36 TRANSMISSION OF AN INFECTIOUS AGENT VIA PRODUCT 18 0.0994
37 PHAEOHYPHOMYCOSIS 46 0.0960
38 ACANTHAMOEBA INFECTION 18 0.0957
39 DYSPLASTIC NAEVUS 34 0.0942
40 MICROSPORIDIA INFECTION 33 0.0940
41 ALTERNARIA INFECTION 34 0.0914
42 CYSTITIS VIRAL 34 0.0888
43 DEHISCENCE 16 0.0847
44 IDIOPATHIC PNEUMONIA SYNDROME 24 0.0805
45 LOWER RESPIRATORY TRACT INFECTION FUNGAL 31 0.0797
46 BLOOD BETA-D-GLUCAN INCREASED 24 0.0782
47 PULMONARY MYCOSIS 58 0.0745
48 FUNGAL TEST POSITIVE 26 0.0741
49 PNEUMONIA FUNGAL 290 0.0734
50 SKIN CANDIDA 38 0.0728
51 FUNGAEMIA 111 0.0705
52 PSEUDOPORPHYRIA 23 0.0673
53 DISORGANISED SPEECH 122 0.0661
54 SOLAR LENTIGO 61 0.0643
55 ACUTE GRAFT VERSUS HOST DISEASE IN LIVER 45 0.0626
56 GALLBLADDER OEDEMA 18 0.0614
57 DYSCHROMATOPSIA 48 0.0579
58 PNEUMOCYSTIS JIROVECII INFECTION 68 0.0569
59 MEDIASTINITIS 33 0.0569
60 INFECTIVE ANEURYSM 28 0.0566
61 LENTIGO 28 0.0565
62 ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE 79 0.0559
63 SQUAMOUS CELL CARCINOMA OF SKIN 336 0.0556
64 RHINOCEREBRAL MUCORMYCOSIS 19 0.0548
65 LUNG TRANSPLANT REJECTION 35 0.0530
66 GRAFT VERSUS HOST DISEASE IN LUNG 25 0.0523
67 BRAIN ABSCESS 131 0.0517
68 HUMAN POLYOMAVIRUS INFECTION 27 0.0508
69 VIRAL HAEMORRHAGIC CYSTITIS 36 0.0506
70 PNEUMONIA NECROTISING 32 0.0495
71 PRODUCT COMPOUNDING QUALITY ISSUE 18 0.0493
72 POLYSEROSITIS 21 0.0493
73 RESPIRATORY TRACT INFECTION FUNGAL 26 0.0492
74 CITROBACTER INFECTION 21 0.0490
75 SINUSITIS FUNGAL 39 0.0486
76 ENTEROCOCCAL SEPSIS 39 0.0481
77 SEPTIC EMBOLUS 40 0.0481
78 CHROMATOPSIA 35 0.0461
79 STENOTROPHOMONAS INFECTION 62 0.0457
80 TRACHEOBRONCHITIS 34 0.0442
81 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 144 0.0436
82 BLASTOMYCOSIS 21 0.0432
83 GRAFT VERSUS HOST DISEASE IN GASTROINTESTINAL TRACT 90 0.0423
84 UREAPLASMA INFECTION 17 0.0417
85 DRUG LEVEL BELOW THERAPEUTIC 229 0.0415
86 ACUTE MYELOID LEUKAEMIA RECURRENT 89 0.0414
87 GRAFT VERSUS HOST DISEASE 297 0.0413
88 ACUTE GRAFT VERSUS HOST DISEASE IN SKIN 114 0.0412
89 DISSEMINATED CRYPTOCOCCOSIS 31 0.0410
90 GLIOSIS 17 0.0396
91 INFECTION IN AN IMMUNOCOMPROMISED HOST 28 0.0390
92 GRAFT VERSUS HOST DISEASE IN SKIN 85 0.0385
93 CORNEAL PERFORATION 24 0.0380
94 PULMONARY CAVITATION 33 0.0379
95 LEUKAEMIA RECURRENT 64 0.0378
96 PHOTOSENSITIVITY REACTION 624 0.0377
97 GRAFT VERSUS HOST DISEASE IN LIVER 27 0.0377
98 OVARIAN FAILURE 20 0.0374
99 DRUG LEVEL INCREASED 619 0.0374
100 ENTEROCOCCAL BACTERAEMIA 39 0.0368
101 RENAL ISCHAEMIA 20 0.0366
102 DYSBIOSIS 30 0.0365
103 HALO VISION 40 0.0354
104 MYCOBACTERIUM ABSCESSUS INFECTION 25 0.0350
105 NECROTISING RETINITIS 22 0.0344
106 CYTOMEGALOVIRUS ENTEROCOLITIS 26 0.0338
107 GASTROINTESTINAL FUNGAL INFECTION 17 0.0330
108 TOXOPLASMOSIS 35 0.0324
109 BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC 30 0.0324
110 SYSTEMIC CANDIDA 77 0.0306
111 DRUG LEVEL ABOVE THERAPEUTIC 138 0.0301
112 FUNGAL SEPSIS 25 0.0301
113 RETINAL ISCHAEMIA 18 0.0295
114 RENAL ABSCESS 24 0.0293
115 ENTEROCOCCAL INFECTION 138 0.0285
116 ACINETOBACTER INFECTION 31 0.0283
117 PNEUMONIA PSEUDOMONAL 43 0.0280
118 PATHOGEN RESISTANCE 252 0.0276
119 PROCALCITONIN INCREASED 32 0.0273
120 ENGRAFTMENT SYNDROME 16 0.0271
121 CHRONIC GRAFT VERSUS HOST DISEASE IN SKIN 25 0.0270
122 ACUTE GRAFT VERSUS HOST DISEASE 122 0.0266
123 ENDOPHTHALMITIS 159 0.0265
124 INFECTIOUS PLEURAL EFFUSION 40 0.0263
125 MICROANGIOPATHIC HAEMOLYTIC ANAEMIA 20 0.0254
126 CYTOMEGALOVIRUS VIRAEMIA 112 0.0252
127 PRODUCT CONTAMINATION MICROBIAL 30 0.0251
128 MULTIPLE ORGAN DYSFUNCTION SYNDROME 712 0.0251
129 IMMUNOSUPPRESSANT DRUG LEVEL DECREASED 30 0.0250
130 VENOOCCLUSIVE LIVER DISEASE 122 0.0247
131 HALLUCINATION, VISUAL 516 0.0244
132 COCCIDIOIDOMYCOSIS 29 0.0243
133 PNEUMONIA CYTOMEGALOVIRAL 47 0.0242
134 SQUAMOUS CELL CARCINOMA 225 0.0239
135 DRUG RESISTANCE 612 0.0238
136 PSEUDOMONAS INFECTION 204 0.0238
137 DRUG LEVEL DECREASED 240 0.0236
138 DIFFERENTIATION SYNDROME 17 0.0232
139 INFECTION REACTIVATION 26 0.0227
140 BK VIRUS INFECTION 76 0.0225
141 CHRONIC GRAFT VERSUS HOST DISEASE 81 0.0224
142 PNEUMONIA CRYPTOCOCCAL 21 0.0222
143 OBLITERATIVE BRONCHIOLITIS 29 0.0221
144 APALLIC SYNDROME 16 0.0220
145 NOCARDIOSIS 56 0.0219
146 ACUTE MYELOID LEUKAEMIA 340 0.0218
147 NEUROLOGICAL DECOMPENSATION 50 0.0216
148 PNEUMOMEDIASTINUM 39 0.0216
149 LUNG ABSCESS 45 0.0214
150 KLEBSIELLA SEPSIS 24 0.0213
151 ACUTE LYMPHOCYTIC LEUKAEMIA 60 0.0212
152 PSEUDOMONAL BACTERAEMIA 18 0.0211
153 APLASIA 41 0.0209
154 POUCHITIS 18 0.0209
155 CYTOMEGALOVIRUS TEST POSITIVE 37 0.0207
156 ADENOVIRUS INFECTION 60 0.0207
157 PULMONARY NOCARDIOSIS 17 0.0206
158 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 53 0.0205
159 HEPATOTOXICITY 443 0.0199
160 CYTOMEGALOVIRUS INFECTION REACTIVATION 87 0.0197
161 COLOUR BLINDNESS 18 0.0196
162 CYSTITIS HAEMORRHAGIC 79 0.0196
163 KLEBSIELLA INFECTION 99 0.0196
164 BLAST CELL COUNT INCREASED 20 0.0191
165 PSEUDOMONAL SEPSIS 33 0.0188
166 BACTERIAL SEPSIS 61 0.0187
167 CHOLESTASIS 359 0.0187
168 PREMATURE MENOPAUSE 17 0.0184
169 BRAIN HERNIATION 55 0.0184
170 DRUG CLEARANCE DECREASED 24 0.0184
171 OCULAR TOXICITY 20 0.0181
172 HUMAN HERPESVIRUS 6 INFECTION 34 0.0180
173 VENOOCCLUSIVE DISEASE 45 0.0180
174 KLEBSIELLA BACTERAEMIA 17 0.0179
175 HYPOGONADISM 18 0.0178
176 MYCOBACTERIUM AVIUM COMPLEX INFECTION 47 0.0175
177 CAPILLARY LEAK SYNDROME 36 0.0174
178 FUNGAL INFECTION 580 0.0174
179 MIXED LIVER INJURY 52 0.0173
180 CRYPTOCOCCOSIS 28 0.0172
181 FUNGAL SKIN INFECTION 69 0.0171
182 MUCOSAL ULCERATION 17 0.0168
183 LUNG CONSOLIDATION 47 0.0168
184 STREPTOCOCCAL BACTERAEMIA 18 0.0165
185 SEPTIC SHOCK 718 0.0165
186 STEM CELL TRANSPLANT 41 0.0164
187 POTENTIATING DRUG INTERACTION 55 0.0164
188 BONE MARROW TRANSPLANT 31 0.0163
189 CHOLESTATIC LIVER INJURY 36 0.0162
190 GASTROINTESTINAL WALL THICKENING 24 0.0160
191 MENINGITIS CRYPTOCOCCAL 28 0.0160
192 PULMONARY ALVEOLAR HAEMORRHAGE 89 0.0159
193 PNEUMONIA KLEBSIELLA 29 0.0158
194 SOMATIC SYMPTOM DISORDER 17 0.0157
195 NEUROTOXICITY 273 0.0156
196 POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 79 0.0155
197 DRUG INTERACTION 2410 0.0152
198 TORSADE DE POINTES 119 0.0152
199 PARAINFLUENZAE VIRUS INFECTION 23 0.0151
200 ENTEROBACTER INFECTION 25 0.0149
201 STRONGYLOIDIASIS 24 0.0148
202 HEPATOSPLENOMEGALY 38 0.0148
203 LUNG OPACITY 39 0.0148
204 CEREBRAL ARTERY EMBOLISM 18 0.0148
205 HYPOPROTEINAEMIA 28 0.0147
206 NEPHROPATHY TOXIC 165 0.0147
207 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 109 0.0145
208 LABELLED DRUG-DRUG INTERACTION ISSUE 21 0.0145
209 CYTOMEGALOVIRUS INFECTION 241 0.0145
210 STAPHYLOCOCCAL SEPSIS 71 0.0144
211 HEPATITIS CHOLESTATIC 86 0.0143
212 NECROTISING COLITIS 18 0.0142
213 EMPYEMA 28 0.0141
214 ESCHERICHIA BACTERAEMIA 33 0.0140
215 NEUTROPENIC COLITIS 29 0.0140
216 FEBRILE NEUTROPENIA 925 0.0139
217 INHIBITORY DRUG INTERACTION 22 0.0139
218 PSEUDOMEMBRANOUS COLITIS 31 0.0139
219 ACUTE LEUKAEMIA 22 0.0136
220 CARDIOVASCULAR INSUFFICIENCY 22 0.0135
221 ACUTE LUNG INJURY 16 0.0135
222 HEPATIC CYTOLYSIS 172 0.0135
223 PULMONARY HAEMORRHAGE 104 0.0133
224 PNEUMONIA BACTERIAL 122 0.0133
225 MULTI-ORGAN FAILURE 228 0.0132
226 PNEUMONIA LEGIONELLA 21 0.0131
227 ESCHERICHIA SEPSIS 38 0.0131
228 DISSEMINATED INTRAVASCULAR COAGULATION 184 0.0131
229 HYPERTRANSAMINASAEMIA 90 0.0129
230 CANDIDA INFECTION 218 0.0129
231 NEUTROPENIC SEPSIS 92 0.0129
232 SUSPECTED OFF LABEL USE 58 0.0128
233 BILIRUBIN CONJUGATED INCREASED 30 0.0128
234 ATYPICAL MYCOBACTERIAL INFECTION 18 0.0127
235 LEUKAEMIA 120 0.0127
236 TOXIC ENCEPHALOPATHY 64 0.0126
237 BRONCHIAL SECRETION RETENTION 16 0.0126
238 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 68 0.0125
239 CANDIDIASIS 50 0.0125
240 HISTOPLASMOSIS 22 0.0124
241 COMA SCALE ABNORMAL 36 0.0124
242 ACUTE RESPIRATORY DISTRESS SYNDROME 218 0.0123
243 APRAXIA 18 0.0121
244 CHEILITIS 65 0.0120
245 THROMBOTIC MICROANGIOPATHY 117 0.0120
246 MULTIPLE-DRUG RESISTANCE 37 0.0119
247 RESPIRATORY FAILURE 867 0.0119
248 PNEUMONIA STAPHYLOCOCCAL 23 0.0116
249 HEPATIC FUNCTION ABNORMAL 435 0.0116
250 ENTHESOPATHY 18 0.0115
251 COMPLICATIONS OF TRANSPLANTED KIDNEY 26 0.0115
252 HISTIOCYTOSIS HAEMATOPHAGIC 34 0.0114
253 TRANSPLANT FAILURE 28 0.0114
254 HALLUCINATIONS, MIXED 48 0.0114
255 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 30 0.0113
256 DYSPHORIA 57 0.0113
257 TRANSPLANT DYSFUNCTION 20 0.0112
258 ILEUS PARALYTIC 50 0.0112
259 ANTIPHOSPHOLIPID SYNDROME 18 0.0112
260 CYTOLYTIC HEPATITIS 37 0.0111
261 LUNG INFILTRATION 98 0.0111
262 STAPHYLOCOCCAL BACTERAEMIA 48 0.0110
263 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 105 0.0110
264 NEUROLOGICAL SYMPTOM 62 0.0108
265 GAMMA-GLUTAMYLTRANSFERASE INCREASED 240 0.0108
266 NECROSIS 60 0.0108
267 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 110 0.0107
268 SPUTUM INCREASED 23 0.0106
269 DEAFNESS BILATERAL 18 0.0106
270 HEPATOCELLULAR INJURY 150 0.0106
271 LUNG INFECTION 164 0.0105
272 RHINOVIRUS INFECTION 41 0.0105
273 ASPARTATE AMINOTRANSFERASE ABNORMAL 16 0.0105
274 MYCOBACTERIAL INFECTION 18 0.0104
275 HYPERLACTACIDAEMIA 28 0.0104
276 DEVICE RELATED SEPSIS 21 0.0104
277 GRANULOMA 36 0.0104
278 SOFT TISSUE INFECTION 19 0.0104
279 ORGANISING PNEUMONIA 51 0.0103
280 BLOOD ALKALINE PHOSPHATASE INCREASED 255 0.0103
281 BURNS SECOND DEGREE 18 0.0103
282 CYTOMEGALOVIRUS CHORIORETINITIS 20 0.0102
283 TRANSPLANT REJECTION 82 0.0102
284 HYPERBILIRUBINAEMIA 106 0.0102
285 LEUKOENCEPHALOPATHY 38 0.0102
286 PANCYTOPENIA 570 0.0102
287 PHOTOPSIA 64 0.0101
288 CELL DEATH 20 0.0101
289 INTERVERTEBRAL DISCITIS 19 0.0101
290 APLASTIC ANAEMIA 52 0.0099
291 FORCED EXPIRATORY VOLUME DECREASED 28 0.0099
292 LIVER ABSCESS 32 0.0099
293 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 49 0.0098
294 SKIN NECROSIS 51 0.0098
295 VENOUS THROMBOSIS LIMB 20 0.0097
296 BLOOD CULTURE POSITIVE 29 0.0097
297 OLIGURIA 60 0.0097
298 HAEMOTHORAX 28 0.0096
299 DRUG-INDUCED LIVER INJURY 301 0.0096
300 CEREBELLAR SYNDROME 21 0.0096
301 BLOOD BILIRUBIN INCREASED 257 0.0095
302 HALLUCINATION 715 0.0095
303 CHEST X-RAY ABNORMAL 29 0.0094
304 HAEMODYNAMIC INSTABILITY 72 0.0094
305 HYPERAMMONAEMIA 47 0.0094
306 STUPOR 30 0.0093
307 PULMONARY MASS 139 0.0093
308 METABOLIC ENCEPHALOPATHY 28 0.0093
309 TUMOUR LYSIS SYNDROME 82 0.0093
310 DELIRIUM 321 0.0092
311 RENAL TUBULAR DISORDER 26 0.0092
312 HYPOPHOSPHATAEMIA 67 0.0091
313 LUNG TRANSPLANT 32 0.0090
314 CYTOPENIA 110 0.0090
315 HYPERCAPNIA 27 0.0090
316 INFLAMMATORY MARKER INCREASED 44 0.0089
317 HEPATITIS TOXIC 23 0.0088
318 EPSTEIN-BARR VIRUS INFECTION 55 0.0088
319 DERMATITIS EXFOLIATIVE 44 0.0088
320 BACTERAEMIA 104 0.0088
321 CYTOKINE RELEASE SYNDROME 175 0.0087
322 BLOOD IMMUNOGLOBULIN E INCREASED 21 0.0087
323 RESPIRATORY ACIDOSIS 34 0.0086
324 HAEMOPTYSIS 239 0.0086
325 STAPHYLOCOCCUS TEST POSITIVE 18 0.0085
326 PNEUMOTHORAX 135 0.0085
327 TORTICOLLIS 18 0.0085
328 BONE MARROW FAILURE 171 0.0084
329 BASAL CELL CARCINOMA 130 0.0083
330 CLOSTRIDIUM DIFFICILE COLITIS 88 0.0083
331 ALTERED STATE OF CONSCIOUSNESS 179 0.0083
332 RENAL TUBULAR ACIDOSIS 18 0.0082
333 TOXIC SKIN ERUPTION 83 0.0082
334 BRAIN OEDEMA 104 0.0082
335 HYPOALBUMINAEMIA 64 0.0082
336 VISUAL DISTURBANCE 47 0.0082
337 ENCEPHALOPATHY 201 0.0082
338 HERPES SIMPLEX 53 0.0081
339 HYPOXIA 285 0.0081
340 LIVER FUNCTION TEST ABNORMAL 233 0.0080
341 ELECTROCARDIOGRAM QT PROLONGED 288 0.0080
342 FEBRILE BONE MARROW APLASIA 34 0.0080
343 CARDIAC TAMPONADE 38 0.0080
344 HYPOKALAEMIA 369 0.0080
345 ENCEPHALITIS 55 0.0079
346 ENDOCARDITIS 40 0.0078
347 PNEUMOCYSTIS JIROVECII PNEUMONIA 78 0.0078
348 LIP BLISTER 21 0.0077
349 TRANSAMINASES INCREASED 171 0.0077
350 HYPOMAGNESAEMIA 107 0.0077
351 POLYOMAVIRUS-ASSOCIATED NEPHROPATHY 18 0.0077
352 MYOCLONUS 91 0.0076
353 HYPERNATRAEMIA 38 0.0076
354 DERMATITIS BULLOUS 55 0.0076
355 CACHEXIA 39 0.0076
356 TRANSPLANT 18 0.0076
357 LONG QT SYNDROME 18 0.0075
358 JAUNDICE CHOLESTATIC 26 0.0074
359 ULCERATIVE KERATITIS 20 0.0073
360 CHOLECYSTITIS ACUTE 41 0.0072
361 ORGAN FAILURE 29 0.0072
362 VENTRICULAR HYPOKINESIA 23 0.0072
363 MUCOSAL INFLAMMATION 187 0.0071
364 BACTERIAL INFECTION 133 0.0071
365 PULMONARY FUNCTION TEST DECREASED 31 0.0071
366 HEPATITIS FULMINANT 21 0.0071
367 PHOTOPHOBIA 131 0.0070
368 CYTOMEGALOVIRUS COLITIS 16 0.0070
369 IMMUNOSUPPRESSION 61 0.0069
370 MYELODYSPLASTIC SYNDROME 100 0.0069
371 HYPOGAMMAGLOBULINAEMIA 45 0.0068
372 PERSECUTORY DELUSION 17 0.0068
373 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 372 0.0068
374 RETINAL HAEMORRHAGE 48 0.0067
375 COAGULOPATHY 112 0.0067
376 LYMPHOPENIA 95 0.0067
377 RALES 39 0.0067
378 CYSTIC FIBROSIS 37 0.0067
379 BLOOD ALBUMIN DECREASED 53 0.0067
380 ACIDOSIS 51 0.0067
381 ABDOMINAL INFECTION 17 0.0066
382 FUNCTIONAL GASTROINTESTINAL DISORDER 23 0.0066
383 NEUTROPHIL COUNT DECREASED 271 0.0066
384 HYDROCEPHALUS 36 0.0066
385 GASTRIC PERFORATION 18 0.0066
386 TOXIC EPIDERMAL NECROLYSIS 100 0.0066
387 STAPHYLOCOCCAL INFECTION 217 0.0066
388 HYPERURICAEMIA 27 0.0066
389 RASH MACULO-PAPULAR 146 0.0066
390 CUSHINGOID 21 0.0065
391 THROMBOTIC THROMBOCYTOPENIC PURPURA 23 0.0065
392 ATELECTASIS 63 0.0065
393 HEPATOMEGALY 64 0.0065
394 PERIPHERAL SENSORY NEUROPATHY 38 0.0065
395 SUNBURN 48 0.0064
396 BRONCHOPNEUMONIA 22 0.0064
397 SEPSIS 714 0.0064
398 ORAL INFECTION 25 0.0064
399 BLOOD LACTATE DEHYDROGENASE INCREASED 101 0.0064
400 PROTEIN TOTAL DECREASED 24 0.0064
401 ARTHRITIS BACTERIAL 26 0.0063
402 HEPATIC FAILURE 189 0.0063
403 ASPARTATE AMINOTRANSFERASE INCREASED 332 0.0062
404 LIVER INJURY 151 0.0061
405 ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 31 0.0061
406 ELECTROLYTE IMBALANCE 71 0.0061
407 LABELLED DRUG-DRUG INTERACTION MEDICATION ERROR 54 0.0061
408 TACHYPNOEA 83 0.0061
409 PLEURAL EFFUSION 369 0.0061
410 MENTAL STATUS CHANGES 168 0.0060
411 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 23 0.0060
412 PROTHROMBIN TIME PROLONGED 36 0.0060
413 HYPERKALAEMIA 209 0.0060
414 SHOCK 137 0.0060
415 BRONCHIECTASIS 40 0.0059
416 MALABSORPTION 31 0.0059
417 LIP PAIN 17 0.0059
418 INTRACRANIAL PRESSURE INCREASED 33 0.0059
419 AGRANULOCYTOSIS 110 0.0059
420 SERUM FERRITIN INCREASED 31 0.0059
421 RESPIRATORY DISTRESS 162 0.0059
422 CARDIAC FAILURE ACUTE 39 0.0058
423 SUBCUTANEOUS ABSCESS 28 0.0058
424 ESCHERICHIA INFECTION 48 0.0058
425 CEREBRAL ISCHAEMIA 30 0.0058
426 UVEITIS 79 0.0058
427 ALANINE AMINOTRANSFERASE INCREASED 356 0.0058
428 BLOOD UREA INCREASED 97 0.0058
429 RENAL IMPAIRMENT 481 0.0057
430 TREATMENT FAILURE 474 0.0057
431 ANURIA 49 0.0057
432 BLOOD MAGNESIUM DECREASED 49 0.0057
433 LUNG NEOPLASM 24 0.0056
434 ADRENAL INSUFFICIENCY 68 0.0056
435 SHOCK HAEMORRHAGIC 45 0.0055
436 RENAL FAILURE ACUTE 234 0.0055
437 VENTRICULAR EXTRASYSTOLES 57 0.0055
438 NEUTROPENIA 746 0.0055
439 INTRAOCULAR PRESSURE INCREASED 70 0.0055
440 PERICARDIAL EFFUSION 125 0.0054
441 ACUTE RESPIRATORY FAILURE 104 0.0054
442 LIVER DISORDER 239 0.0054
443 C-REACTIVE PROTEIN INCREASED 196 0.0054
444 ENTEROCOLITIS 31 0.0054
445 ATYPICAL PNEUMONIA 16 0.0053
446 GUILLAIN-BARRE SYNDROME 25 0.0052
447 RHABDOMYOLYSIS 214 0.0051
448 VISUAL FIELD DEFECT 37 0.0051
449 CENTRAL NERVOUS SYSTEM LESION 70 0.0051
450 MENINGITIS 34 0.0051
451 HEMIPARESIS 86 0.0051
452 BLOOD CREATININE INCREASED 331 0.0051
453 HALLUCINATION, AUDITORY 80 0.0050
454 SKIN INFECTION 56 0.0050
455 AUTOIMMUNE HAEMOLYTIC ANAEMIA 17 0.0050
456 OESOPHAGITIS 54 0.0049
457 HEMIPLEGIA 41 0.0049
458 PULMONARY TUBERCULOSIS 21 0.0049
459 ACUTE HEPATIC FAILURE 67 0.0049
460 PLATELET COUNT DECREASED 522 0.0049
461 LEUKOPENIA 241 0.0048
462 DISEASE PROGRESSION 570 0.0048
463 HEPATIC ENZYME ABNORMAL 24 0.0048
464 ACUTE PULMONARY OEDEMA 27 0.0048
465 HAEMORRHAGE SUBCUTANEOUS 17 0.0048
466 VENTRICULAR FIBRILLATION 53 0.0048
467 PSYCHIATRIC SYMPTOM 35 0.0047
468 NERVOUS SYSTEM DISORDER 148 0.0047
469 VISUAL ACUITY REDUCED 156 0.0047
470 ABSCESS LIMB 20 0.0047
471 VENTRICULAR TACHYCARDIA 77 0.0047
472 SINUS TACHYCARDIA 66 0.0046
473 CHRONIC LYMPHOCYTIC LEUKAEMIA 22 0.0046
474 VASCULAR DEVICE INFECTION 21 0.0046
475 LEFT VENTRICULAR DYSFUNCTION 31 0.0046
476 FAILURE TO THRIVE 24 0.0046
477 HEPATITIS ACUTE 30 0.0046
478 DEPRESSED LEVEL OF CONSCIOUSNESS 181 0.0046
479 DEVICE RELATED INFECTION 70 0.0045
480 AZOTAEMIA 18 0.0045
481 ACUTE KIDNEY INJURY 685 0.0045
482 PAPILLOEDEMA 20 0.0044
483 THROMBOCYTOPENIA 494 0.0044
484 LYMPHOCYTE COUNT DECREASED 78 0.0044
485 CHAPPED LIPS 19 0.0044
486 CARDIOPULMONARY FAILURE 17 0.0044
487 SKIN MASS 29 0.0043
488 AMYLASE INCREASED 16 0.0043
489 EMBOLISM 36 0.0043
490 MYELOSUPPRESSION 156 0.0043
491 LEUKOCYTOSIS 78 0.0043
492 HAEMODIALYSIS 36 0.0043
493 HAEMOLYSIS 33 0.0043
494 HYPERTRIGLYCERIDAEMIA 25 0.0043
495 POLYNEUROPATHY 51 0.0043
496 ENTERITIS 27 0.0042
497 CEREBRAL HAEMORRHAGE 151 0.0042
498 LUNG DISORDER 206 0.0042
499 PYREXIA 1454 0.0042
500 PARTIAL SEIZURES 22 0.0042
501 PNEUMONIA 1358 0.0042
502 ILEUS 52 0.0042
503 SUPRAVENTRICULAR TACHYCARDIA 40 0.0042
504 DRUG ERUPTION 74 0.0042
505 ISCHAEMIA 19 0.0041
506 SPLENOMEGALY 48 0.0041
507 INTERSTITIAL LUNG DISEASE 198 0.0041
508 ASCITES 120 0.0041
509 COVID-19 PNEUMONIA 48 0.0041
510 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 24 0.0040
511 HYPERCALCAEMIA 50 0.0040
512 SKIN LESION 111 0.0040
513 RENAL FAILURE 532 0.0040
514 VISUAL IMPAIRMENT 496 0.0040
515 HEPATIC ENCEPHALOPATHY 37 0.0040
516 HEPATITIS 101 0.0039
517 MYOPATHY 34 0.0039
518 ATRIAL FLUTTER 31 0.0039
519 MENTAL DISORDER 169 0.0039
520 METABOLIC ACIDOSIS 124 0.0039
521 CONDITION AGGRAVATED 1157 0.0038
522 STREPTOCOCCAL INFECTION 21 0.0038
523 RENAL TUBULAR NECROSIS 37 0.0038
524 BLOOD DISORDER 30 0.0037
525 LIVER FUNCTION TEST INCREASED 80 0.0037
526 SKIN TOXICITY 21 0.0037
527 ATAXIA 44 0.0037
528 OSTEOMYELITIS 67 0.0037
529 PANCREATITIS ACUTE 83 0.0037
530 HYPONATRAEMIA 207 0.0037
531 HEPATIC ENZYME INCREASED 250 0.0037
532 ARTHRITIS INFECTIVE 17 0.0037
533 BREATH SOUNDS ABNORMAL 18 0.0036
534 HYPERGLYCAEMIA 133 0.0036
535 NEPHROTIC SYNDROME 25 0.0036
536 HYPOCALCAEMIA 69 0.0036
537 CIRCULATORY COLLAPSE 62 0.0036
538 DIFFUSE LARGE B-CELL LYMPHOMA 28 0.0036
539 ABDOMINAL TENDERNESS 18 0.0036
540 GENERALISED OEDEMA 44 0.0036
541 GASTROINTESTINAL TOXICITY 17 0.0035
542 HYPERTHERMIA 27 0.0035
543 PNEUMONITIS 96 0.0035
544 RESPIRATORY DISORDER 105 0.0035
545 EOSINOPHILIA 61 0.0035
546 HERPES VIRUS INFECTION 20 0.0035
547 EPILEPSY 106 0.0035
548 RESPIRATORY SYNCYTIAL VIRUS INFECTION 30 0.0034
549 ORAL DISORDER 25 0.0034
550 INFECTION 492 0.0034
551 MALNUTRITION 38 0.0034
552 THERAPY NON-RESPONDER 152 0.0034
553 FLUID OVERLOAD 49 0.0034
554 ECCHYMOSIS 23 0.0034
555 PETECHIAE 35 0.0034
556 SUBARACHNOID HAEMORRHAGE 34 0.0033
557 SEROTONIN SYNDROME 64 0.0033
558 SINUS BRADYCARDIA 32 0.0033
559 AUTOIMMUNE HEPATITIS 23 0.0033
560 DRUG INEFFECTIVE 4334 0.0033
561 STEVENS-JOHNSON SYNDROME 73 0.0033
562 CEREBRAL INFARCTION 80 0.0033
563 LYMPHOMA 50 0.0032
564 MYOSITIS 29 0.0032
565 WHITE BLOOD CELL COUNT DECREASED 350 0.0032
566 RESPIRATORY TRACT INFECTION 84 0.0032
567 NEUTROPHIL COUNT INCREASED 33 0.0032
568 LUPUS-LIKE SYNDROME 29 0.0032
569 HICCUPS 26 0.0032
570 SKIN CANCER 68 0.0032
571 HAEMATOTOXICITY 30 0.0032
572 CARDIOTOXICITY 28 0.0031
573 WHITE BLOOD CELL COUNT ABNORMAL 20 0.0031
574 ABSCESS 50 0.0031
575 NORMAL NEWBORN 17 0.0031
576 HAEMOLYTIC ANAEMIA 28 0.0031
577 JAUNDICE 84 0.0031
578 CHOLECYSTITIS 37 0.0031
579 RENAL DISORDER 144 0.0031
580 PRODUCT USE IN UNAPPROVED INDICATION 765 0.0031
581 MOUTH ULCERATION 65 0.0031
582 CLOSTRIDIUM DIFFICILE INFECTION 67 0.0031
583 DECUBITUS ULCER 25 0.0031
584 PULMONARY OEDEMA 136 0.0030
585 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 25 0.0030
586 DISORIENTATION 120 0.0030
587 HAEMATOCRIT DECREASED 60 0.0030
588 DISEASE RECURRENCE 143 0.0030
589 PERITONITIS 62 0.0030
590 COMPRESSION FRACTURE 16 0.0030
591 BLOOD POTASSIUM DECREASED 89 0.0030
592 AGITATION 217 0.0030
593 BLOOD CREATINE PHOSPHOKINASE INCREASED 85 0.0029
594 BLOOD URIC ACID INCREASED 17 0.0029
595 HAEMORRHAGE INTRACRANIAL 44 0.0029
596 CARDIAC FAILURE 235 0.0029
597 CARDIAC ARREST 240 0.0029
598 GENERALISED TONIC-CLONIC SEIZURE 48 0.0029
599 ANAEMIA 552 0.0029
600 LARGE INTESTINE PERFORATION 20 0.0029
601 OFF LABEL USE 2510 0.0029
602 MOUTH HAEMORRHAGE 21 0.0029
603 CONFUSIONAL STATE 460 0.0028
604 HYPERLIPIDAEMIA 34 0.0028
605 IMMUNODEFICIENCY 42 0.0028
606 FACIAL PARALYSIS 24 0.0028
607 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 17 0.0028
608 PRODUCTIVE COUGH 133 0.0028
609 TRANSFUSION 29 0.0028
610 COMA 131 0.0027
611 WOUND INFECTION 30 0.0027
612 NEUROPATHY PERIPHERAL 260 0.0027
613 PURPURA 24 0.0027
614 UNRESPONSIVE TO STIMULI 70 0.0027
615 CELLULITIS 136 0.0027
616 VASCULITIS 31 0.0027
617 STATUS EPILEPTICUS 30 0.0027
618 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 68 0.0026
619 SPUTUM DISCOLOURED 25 0.0026
620 HOSPICE CARE 26 0.0026
621 URINE OUTPUT DECREASED 23 0.0026
622 EYE MOVEMENT DISORDER 18 0.0026
623 INCOHERENT 17 0.0026
624 CONCOMITANT DISEASE AGGRAVATED 16 0.0026
625 RESPIRATORY RATE INCREASED 23 0.0026
626 RED BLOOD CELL COUNT DECREASED 74 0.0026
627 CARDIO-RESPIRATORY ARREST 108 0.0026
628 VISION BLURRED 350 0.0025
629 NO THERAPEUTIC RESPONSE 31 0.0025
630 WHITE BLOOD CELL COUNT INCREASED 97 0.0025
631 MYDRIASIS 32 0.0025
632 RESTLESSNESS 91 0.0025
633 HAEMATURIA 85 0.0025
634 TOXICITY TO VARIOUS AGENTS 418 0.0025
635 NEPHROPATHY 23 0.0025
636 HAEMOGLOBIN DECREASED 252 0.0025
637 SKIN HYPERPIGMENTATION 21 0.0024
638 VITREOUS FLOATERS 24 0.0024
639 BLINDNESS 99 0.0024
640 HYPOTENSION 485 0.0024
641 HYPOGLYCAEMIA 117 0.0024
642 INTESTINAL PERFORATION 27 0.0024
643 ATRIAL FIBRILLATION 234 0.0024
644 GENERAL PHYSICAL HEALTH DETERIORATION 273 0.0024
645 ORAL CANDIDIASIS 31 0.0024
646 APHASIA 71 0.0023
647 DRUG TOXICITY 32 0.0023
648 OEDEMA 127 0.0023
649 DIALYSIS 33 0.0023
650 BLOOD CALCIUM DECREASED 26 0.0023
651 EYE PAIN 130 0.0023
652 BLISTER 126 0.0022
653 TACHYCARDIA 199 0.0022
654 MELAENA 49 0.0022
655 BLOOD POTASSIUM INCREASED 36 0.0022
656 MITRAL VALVE INCOMPETENCE 25 0.0022
657 ATRIOVENTRICULAR BLOCK 17 0.0022
658 FULL BLOOD COUNT DECREASED 44 0.0022
659 ORTHOSTATIC HYPOTENSION 38 0.0022
660 THERAPY PARTIAL RESPONDER 34 0.0022
661 HAEMORRHAGIC STROKE 17 0.0022
662 ANOREXIA 28 0.0022
663 SUBDURAL HAEMATOMA 31 0.0022
664 COLITIS 82 0.0022
665 BODY TEMPERATURE INCREASED 44 0.0022
666 BRADYCARDIA 114 0.0021
667 HEPATIC STEATOSIS 40 0.0021
668 TRICUSPID VALVE INCOMPETENCE 17 0.0021
669 IMMUNE SYSTEM DISORDER 28 0.0021
670 DRUG INTOLERANCE 202 0.0021
671 ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS 16 0.0021
672 BLINDNESS UNILATERAL 29 0.0021
673 OEDEMA PERIPHERAL 250 0.0020
674 RASH ERYTHEMATOUS 98 0.0020
675 PRODUCT USE ISSUE 383 0.0020
676 DYSARTHRIA 76 0.0020
677 HYPOTONIA 20 0.0020
678 NODULE 26 0.0020
679 GASTROINTESTINAL HAEMORRHAGE 166 0.0020
680 EYELID OEDEMA 23 0.0020
681 PULMONARY CONGESTION 26 0.0020
682 INTERNATIONAL NORMALISED RATIO INCREASED 56 0.0020
683 PRESCRIBED OVERDOSE 38 0.0020
684 CARDIOMYOPATHY 29 0.0020
685 PYELONEPHRITIS 17 0.0020
686 PNEUMONIA ASPIRATION 49 0.0020
687 RETINAL DETACHMENT 18 0.0020
688 CARDIOGENIC SHOCK 28 0.0019
689 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 138 0.0019
690 OXYGEN SATURATION DECREASED 109 0.0019
691 SKIN DISORDER 64 0.0019
692 BLOOD COUNT ABNORMAL 29 0.0019
693 FACE OEDEMA 32 0.0019
694 OBSTRUCTIVE AIRWAYS DISORDER 21 0.0019
695 STOMATITIS 114 0.0019
696 CONVULSION 107 0.0019
697 OCULAR DISCOMFORT 21 0.0019
698 BONE DISORDER 34 0.0019
699 MOTOR DYSFUNCTION 19 0.0019
700 HYPOPHAGIA 47 0.0018
701 ERYTHEMA MULTIFORME 17 0.0018
702 HAEMATOMA 47 0.0018
703 NEOPLASM PROGRESSION 63 0.0018
704 BLOOD PRESSURE DECREASED 120 0.0018
705 BLOOD SODIUM DECREASED 34 0.0018
706 EJECTION FRACTION DECREASED 28 0.0018
707 PANCREATITIS 95 0.0018
708 SMALL INTESTINAL OBSTRUCTION 22 0.0018
709 BLOOD TEST ABNORMAL 25 0.0018
710 TUBULOINTERSTITIAL NEPHRITIS 33 0.0018
711 HEPATIC CIRRHOSIS 33 0.0018
712 MUSCLE ATROPHY 22 0.0017
713 DEATH 1483 0.0017
714 VIRAL INFECTION 57 0.0017
715 SUDDEN DEATH 18 0.0017
716 PHARYNGITIS 21 0.0017
717 BONE PAIN 98 0.0017
718 EYELID PTOSIS 17 0.0017
719 ARRHYTHMIA 79 0.0017
720 CHROMATURIA 37 0.0016
721 INTENTIONAL PRODUCT USE ISSUE 142 0.0016
722 HAEMATEMESIS 41 0.0016
723 DIPLOPIA 42 0.0016
724 INFLAMMATION 83 0.0016
725 DEAFNESS 42 0.0016
726 GASTROENTERITIS 23 0.0016
727 DYSURIA 58 0.0016
728 SKIN EXFOLIATION 132 0.0016
729 CHOLELITHIASIS 51 0.0016
730 LYMPHADENOPATHY 55 0.0016
731 CARDIOMEGALY 19 0.0015
732 DYSPHAGIA 146 0.0015
733 PULMONARY HYPERTENSION 32 0.0015
734 COUGH 430 0.0015
735 PULMONARY FIBROSIS 29 0.0015
736 DECREASED APPETITE 350 0.0015
737 DERMATITIS 31 0.0015
738 BRONCHOSPASM 21 0.0015
739 PRODUCT PRESCRIBING ISSUE 32 0.0015
740 MANIA 24 0.0015
741 TREMOR 242 0.0015
742 ERYTHEMA 298 0.0014
743 GASTROINTESTINAL DISORDER 129 0.0014
744 THERAPEUTIC RESPONSE DECREASED 87 0.0014
745 LABORATORY TEST ABNORMAL 42 0.0014
746 PROTEINURIA 27 0.0014
747 DEHYDRATION 188 0.0014
748 POST PROCEDURAL COMPLICATION 27 0.0014
749 RASH PAPULAR 31 0.0014
750 RESPIRATORY ARREST 38 0.0014
751 CHILLS 161 0.0014
752 MUSCULAR WEAKNESS 156 0.0014
753 BEDRIDDEN 18 0.0014
754 PERICARDITIS 23 0.0014
755 MASS 19 0.0014
756 DERMATITIS ALLERGIC 17 0.0014
757 DYSPNOEA 758 0.0013
758 SEIZURE 154 0.0013
759 ORAL HERPES 26 0.0013
760 HERPES ZOSTER 76 0.0013
761 SPEECH DISORDER 69 0.0013
762 NEURALGIA 32 0.0013
763 GASTRIC ULCER 25 0.0013
764 SKIN ULCER 34 0.0013
765 CONTRAINDICATED PRODUCT ADMINISTERED 39 0.0013
766 ABDOMINAL PAIN 299 0.0013
767 BALANCE DISORDER 111 0.0013
768 EPISTAXIS 96 0.0013
769 FEEDING DISORDER 26 0.0013
770 LOWER RESPIRATORY TRACT INFECTION 58 0.0013
771 DEEP VEIN THROMBOSIS 82 0.0013
772 TREATMENT NONCOMPLIANCE 69 0.0013
773 VOMITING 591 0.0013
774 HAEMORRHAGE 131 0.0013
775 ORAL PAIN 28 0.0012
776 UPPER GASTROINTESTINAL HAEMORRHAGE 21 0.0012
777 DYSPNOEA EXERTIONAL 47 0.0012
778 ABNORMAL BEHAVIOUR 49 0.0012
779 BRONCHITIS 90 0.0012
780 BRAIN FOG 19 0.0012
781 HYPOACUSIS 52 0.0012
782 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 63 0.0012
783 DIARRHOEA 778 0.0012
784 FAECES DISCOLOURED 26 0.0012
785 SINUSITIS 122 0.0012
786 PARALYSIS 17 0.0012
787 PLASMA CELL MYELOMA 46 0.0012
788 INFUSION RELATED REACTION 77 0.0012
789 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 34 0.0012
790 RASH GENERALISED 30 0.0012
791 EYE DISORDER 38 0.0012
792 COORDINATION ABNORMAL 16 0.0011
793 RASH 500 0.0011
794 INTERVERTEBRAL DISC PROTRUSION 25 0.0011
795 LACTIC ACIDOSIS 37 0.0011
796 GLAUCOMA 22 0.0011
797 ASTHENIA 429 0.0011
798 TASTE DISORDER 23 0.0011
799 CONJUNCTIVITIS 21 0.0011
800 CYSTITIS 36 0.0011
801 CONSTIPATION 246 0.0011
802 HAEMORRHOIDS 22 0.0011
803 SENSORY DISTURBANCE 18 0.0011
804 ABDOMINAL DISTENSION 117 0.0011
805 FLUID RETENTION 57 0.0011
806 OSTEOPENIA 17 0.0011
807 SOMNOLENCE 222 0.0011
808 MYALGIA 187 0.0011
809 SPINAL FRACTURE 22 0.0011
810 LETHARGY 63 0.0011
811 HEART RATE INCREASED 108 0.0011
812 WEIGHT DECREASED 304 0.0011
813 MALIGNANT NEOPLASM PROGRESSION 111 0.0011
814 CYANOSIS 17 0.0011
815 NIGHTMARE 37 0.0011
816 AGGRESSION 53 0.0011
817 COGNITIVE DISORDER 49 0.0010
818 LOSS OF CONSCIOUSNESS 133 0.0010
819 LOCALISED INFECTION 25 0.0010
820 HYPOTHYROIDISM 33 0.0010
821 HIP FRACTURE 33 0.0010
822 GASTRITIS 27 0.0010
823 HYPERTENSION 217 0.0010
824 PSYCHOMOTOR HYPERACTIVITY 17 0.0010
825 PSYCHOTIC DISORDER 30 0.0010
826 ACTIVITIES OF DAILY LIVING IMPAIRED 20 0.0010
827 GALLBLADDER DISORDER 18 0.0010
828 PRODUCT PRESCRIBING ERROR 24 0.0010
829 NAUSEA 795 0.0010
830 NEOPLASM MALIGNANT 67 0.0010
831 MUSCLE TWITCHING 23 0.0010
832 DRUG EFFECT INCOMPLETE 36 0.0010
833 MUSCULOSKELETAL DISCOMFORT 17 0.0010
834 INFLUENZA 110 0.0010
835 PARAESTHESIA 154 0.0010
836 PULMONARY EMBOLISM 93 0.0010
837 LOCAL SWELLING 17 0.0010
838 UPPER RESPIRATORY TRACT INFECTION 45 0.0010
839 DIABETES MELLITUS 74 0.0010
840 DISTURBANCE IN ATTENTION 52 0.0010
841 WHEEZING 57 0.0010
842 BLOOD PRESSURE FLUCTUATION 23 0.0010
843 ACUTE MYOCARDIAL INFARCTION 28 0.0009
844 ABNORMAL DREAMS 26 0.0009
845 CHEST PAIN 173 0.0009
846 THROMBOSIS 75 0.0009
847 NIGHT SWEATS 30 0.0009
848 FREQUENT BOWEL MOVEMENTS 25 0.0009
849 SWELLING FACE 60 0.0009
850 GAIT DISTURBANCE 176 0.0009
851 RENAL INJURY 27 0.0009
852 CARDIOVASCULAR DISORDER 23 0.0009
853 BLOOD TRIGLYCERIDES INCREASED 16 0.0009
854 HYPOAESTHESIA 135 0.0009
855 INSOMNIA 238 0.0009
856 URINARY TRACT INFECTION 151 0.0009
857 ACCIDENTAL OVERDOSE 32 0.0009
858 COVID-19 153 0.0009
859 CARDIAC FAILURE CONGESTIVE 70 0.0009
860 PRESYNCOPE 21 0.0009
861 ANGIOEDEMA 38 0.0009
862 ANAPHYLACTIC REACTION 47 0.0008
863 URINARY RETENTION 28 0.0008
864 DYSKINESIA 34 0.0008
865 POOR QUALITY SLEEP 18 0.0008
866 HAEMATOCHEZIA 46 0.0008
867 DRUG ADMINISTRATION ERROR 25 0.0008
868 MALAISE 356 0.0008
869 PALLOR 22 0.0008
870 LUNG NEOPLASM MALIGNANT 33 0.0008
871 SYNCOPE 80 0.0008
872 HEART RATE DECREASED 28 0.0008
873 LACRIMATION INCREASED 24 0.0008
874 FALL 264 0.0008
875 CHEST DISCOMFORT 81 0.0008
876 RASH MACULAR 27 0.0008
877 ABASIA 19 0.0008
878 ALOPECIA 149 0.0008
879 CATARACT 45 0.0008
880 OVERDOSE 163 0.0008
881 OSTEOPOROSIS 31 0.0008
882 URINARY INCONTINENCE 22 0.0007
883 BACK PAIN 172 0.0007
884 CARDIAC DISORDER 68 0.0007
885 RASH PRURITIC 39 0.0007
886 DYSSTASIA 21 0.0007
887 SKIN DISCOLOURATION 33 0.0007
888 MEMORY IMPAIRMENT 97 0.0007
889 MENTAL IMPAIRMENT 17 0.0007
890 WEIGHT INCREASED 157 0.0007
891 LIMB INJURY 19 0.0007
892 HEADACHE 433 0.0007
893 MOVEMENT DISORDER 22 0.0007
894 WOUND 19 0.0007
895 AMNESIA 44 0.0007
896 SYSTEMIC LUPUS ERYTHEMATOSUS 24 0.0007
897 NEPHROLITHIASIS 31 0.0007
898 HYPERHIDROSIS 87 0.0007
899 ARTHRITIS 53 0.0007
900 DIZZINESS 336 0.0007
901 VERTIGO 41 0.0007
902 MUSCULOSKELETAL PAIN 35 0.0007
903 HYPERSENSITIVITY 124 0.0007
904 ABDOMINAL DISCOMFORT 112 0.0007
905 HEAD INJURY 21 0.0007
906 INTESTINAL OBSTRUCTION 25 0.0007
907 NERVOUSNESS 34 0.0007
908 SEDATION 17 0.0006
909 ASTHMA 73 0.0006
910 PERIPHERAL SWELLING 97 0.0006
911 FATIGUE 489 0.0006
912 BURNING SENSATION 44 0.0006
913 ILL-DEFINED DISORDER 38 0.0006
914 HOSPITALISATION 96 0.0006
915 GYNAECOMASTIA 19 0.0006
916 NASAL CONGESTION 36 0.0006
917 ABDOMINAL PAIN UPPER 126 0.0006
918 MEDICATION ERROR 34 0.0006
919 COLITIS ULCERATIVE 27 0.0006
920 POLLAKIURIA 25 0.0006
921 DEPRESSION 136 0.0006
922 OROPHARYNGEAL PAIN 55 0.0006
923 EYE SWELLING 22 0.0006
924 ARTHRALGIA 243 0.0006
925 SLEEP DISORDER 41 0.0006
926 DIVERTICULITIS 16 0.0006
927 CONTUSION 55 0.0006
928 LIP SWELLING 19 0.0006
929 THERAPEUTIC RESPONSE UNEXPECTED 25 0.0006
930 DRY MOUTH 45 0.0006
931 PAIN IN EXTREMITY 158 0.0005
932 INTENTIONAL PRODUCT MISUSE 46 0.0005
933 SWELLING 49 0.0005
934 OSTEONECROSIS 17 0.0005
935 BLOOD PRESSURE INCREASED 79 0.0005
936 RHINORRHOEA 33 0.0005
937 MATERNAL EXPOSURE DURING PREGNANCY 45 0.0005
938 CEREBROVASCULAR ACCIDENT 85 0.0005
939 TINNITUS 23 0.0005
940 CHRONIC KIDNEY DISEASE 38 0.0005
941 IRRITABILITY 30 0.0005
942 MUSCLE SPASMS 91 0.0005
943 FEELING ABNORMAL 118 0.0005
944 UNEVALUABLE EVENT 37 0.0005
945 PALPITATIONS 55 0.0005
946 DRUG EFFECT DECREASED 25 0.0005
947 NO ADVERSE EVENT 84 0.0005
948 INFLUENZA LIKE ILLNESS 38 0.0005
949 DYSPHONIA 27 0.0005
950 FLATULENCE 26 0.0005
951 PAIN 274 0.0004
952 ADVERSE DRUG REACTION 40 0.0004
953 DISCOMFORT 27 0.0004
954 ILLNESS 44 0.0004
955 DYSPEPSIA 42 0.0004
956 PRURITUS 164 0.0004
957 ADVERSE EVENT 39 0.0004
958 OCULAR HYPERAEMIA 20 0.0004
959 BLOOD GLUCOSE DECREASED 20 0.0004
960 NASOPHARYNGITIS 76 0.0004
961 BLOOD GLUCOSE INCREASED 77 0.0004
962 ANXIETY 116 0.0004
963 JOINT SWELLING 49 0.0004
964 THROAT IRRITATION 18 0.0004
965 NECK PAIN 22 0.0004
966 DYSGEUSIA 29 0.0004
967 GASTROOESOPHAGEAL REFLUX DISEASE 31 0.0004
968 MOBILITY DECREASED 27 0.0004
969 SUICIDAL IDEATION 33 0.0004
970 DRY SKIN 48 0.0004
971 URTICARIA 58 0.0003
972 HOT FLUSH 26 0.0003
973 ARTHROPATHY 19 0.0003
974 PRODUCT DOSE OMISSION 22 0.0003
975 FLUSHING 34 0.0003
976 UNDERDOSE 24 0.0003
977 DRY EYE 16 0.0003
978 INTENTIONAL OVERDOSE 19 0.0003
979 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 52 0.0003
980 MYOCARDIAL INFARCTION 50 0.0003
981 FOETAL EXPOSURE DURING PREGNANCY 23 0.0003
982 ACNE 21 0.0003
983 PRODUCT DOSE OMISSION ISSUE 80 0.0003
984 FEELING HOT 16 0.0003
985 EXPOSURE DURING PREGNANCY 16 0.0003
986 INCORRECT DOSE ADMINISTERED 58 0.0003
987 THERAPY INTERRUPTED 18 0.0003
988 MIGRAINE 20 0.0002
989 MUSCULOSKELETAL STIFFNESS 18 0.0002
990 EMOTIONAL DISTRESS 23 0.0002
991 DRUG DOSE OMISSION 31 0.0002
992 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 38 0.0002
993 ACCIDENTAL EXPOSURE TO PRODUCT 18 0.0002
994 RHEUMATOID ARTHRITIS 17 0.0001